2.1 MGUS (2014 IMWG Criteria)

MGUS is defined by three simultaneous requirements (1,2):

Light-chain MGUS is additionally defined by an abnormal sFLC ratio, increased involved light chain level, and urinary monoclonal protein <500 mg/24h (1,11).

2.2 Smoldering Multiple Myeloma

SMM occupies the intermediate space and is defined by (1):

2.3 Multiple Myeloma (2014 IMWG Updated Criteria)

The 2014 IMWG consensus represented a paradigm shift by adding three validated biomarkers of near-inevitable progression—the SLiM criteria—to the established CRAB features as myeloma-defining events (1,12).

CRAB Features (End-Organ Damage):

SLiM Biomarkers (Myeloma-Defining Events Without CRAB):

⚠️ Warning: The presence of ANY single SLiM biomarker, even in the absence of CRAB features, is now sufficient to diagnose MM requiring treatment. Approximately 20% of patients who would previously have been classified as SMM are reclassified as MM under the 2014 criteria (12). A real-world registry study (ANZ MRDR, n=3,489) confirmed that SLiM-defined patients had improved progression-free survival (37.5 vs. 32.2 months) and overall survival (80.9 vs. 73.2 months) compared to CRAB-defined patients, supporting the benefit of earlier diagnosis (16).

3.1 Serum Protein Electrophoresis (SPEP)

SPEP separates serum proteins by charge migration through an agarose gel or capillary system. The M-spike appears as a discrete band, typically in the gamma region, and is quantified by densitometric integration of the area under the peak relative to total protein (8,17).

Strengths: - Widely available, inexpensive - Well-established thresholds (e.g., 3 g/dL cutoff validated on gel SPEP) - Decades of clinical validation

Limitations: - Detection limit approximately 0.2–0.5 g/dL (17) - M-proteins migrating in the beta region (common with IgA) may be obscured by transferrin, leading to underestimation or failure to detect (6,8) - Densitometric quantification is an indirect measurement influenced by total protein concentration and background polyclonal immunoglobulins - Cannot differentiate therapeutic monoclonal antibodies from disease M-protein

3.2 Capillary Zone Electrophoresis (CZE)

CZE has largely replaced gel-based SPEP in many reference laboratories. It offers improved resolution and reproducibility, with the ability to detect smaller M-proteins through better peak separation. However, the quantification principle remains fundamentally similar—absorbance in a defined electrophoretic zone (8).

CZE with immunosubtraction (as used at Mayo Clinic) can specifically isolate the monoclonal component, potentially providing a more precise measurement than standard densitometry (6,18).

3.3 Mass Spectrometry: MASS-FIX (MALDI-TOF MS)

MASS-FIX, developed at Mayo Clinic by Murray et al., uses nanobody immunoenrichment coupled with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Since 2018, it has replaced serum immunofixation for M-protein detection and isotyping at Mayo Clinic Rochester (6,7,18,19).

Advantages over conventional methods: - Superior sensitivity for M-protein detection compared to immunofixation electrophoresis (IFE) (6,19) - Ability to determine the precise molecular mass of the monoclonal immunoglobulin, creating a unique molecular “fingerprint” (18) - Differentiation of therapeutic monoclonal antibodies (e.g., daratumumab) from disease M-protein (6,7) - Detection of light chain N-glycosylation, which has diagnostic implications for AL amyloidosis and cold agglutinin disease (19) - Now endorsed by the IMWG as an alternative to immunofixation (7)

In a cross-sectional study of 6,315 patients with MASS-FIX performed at Mayo Clinic, 65% had a positive result across a wide spectrum of plasma cell disorders (19).

Clinical Pearl: The IMWG Mass Spectrometry Committee Report (2021) formally recognized MASS-FIX as a viable alternative to immunofixation, marking the first major methodological advancement in M-protein screening since gel electrophoresis was established in the 1960s (7).

3.4 Quantitative Differences Between Methods

The practical clinical issue: M-protein concentrations measured by different methods are not always interchangeable.

Discrepancies of 0.3–0.5 g/dL or more between laboratories and methods are clinically meaningful when they shift a patient across the 3 g/dL threshold separating MGUS from SMM, or when monitoring treatment response where a 50% M-protein reduction defines partial response.

⚠️ Warning: Serial monitoring should use the same method at the same laboratory. Switching between gel SPEP, CZE, and mass spectrometry-based quantification introduces variability that may be mistaken for disease progression or treatment response. This is particularly critical for M-proteins that comigrate in the beta region.

3.5 Serum Free Light Chains (sFLC)

The serum free light chain assay (Freelite™, The Binding Site) measures unbound κ and λ light chains. The normal κ/λ ratio is approximately 0.26–1.65 (3,14). Key applications include:

• MGUS risk stratification: Abnormal sFLC ratio is one of three risk factors in the Mayo 2005 model (3)
• Myeloma-defining event: Involved/uninvolved ratio ≥100 with involved FLC ≥100 mg/L (1)
• Monitoring light chain-only disease: sFLC is essential for non-secretory or light chain myeloma where SPEP may be negative (14,17)
• Renal considerations: FLC reference intervals should be adjusted for renal function, as differential filtration in renal failure can alter the κ/λ ratio independent of clonality (20)

4.1 Mayo Clinic MGUS Risk Stratification Model (2005)

Rajkumar et al. developed this model from the Olmsted County, Minnesota population-based MGUS cohort (3,4). Three independent risk factors predict progression:

20-Year Absolute Risk of Progression:

A 2025 validation study from Mayo Clinic (Blood. 2025;145(3):325–333) comparing progression risk in population-screened vs. clinically detected MGUS confirmed that the risk stratification model performed similarly regardless of detection method, with cumulative incidence of progression at 25 years of 11.1% in screened vs. 10.1% in clinically detected MGUS (20).

A longitudinal reassessment study from Heidelberg (2024) confirmed that all three major MGUS risk models (Mayo 2005, Sweden 2014, NCI 2019) reliably distinguished risk of progression both at baseline and upon yearly reassessment (21).

4.2 PETHEMA/GEM Model (Spanish Group)

This model uses bone marrow multiparameter flow cytometry to assess (22):

Patients with both risk factors had a 5-year progression rate of approximately 72% in SMM (22,23). However, concordance with the Mayo models is relatively low (approximately 27–45%), reflecting that the models capture different biological dimensions of risk (23).

4.3 iStopMM Prediction Model for Bone Marrow Involvement (2024)

The Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study — the world’s first population-wide screening program for myeloma precursors, enrolling >75,000 Icelanders age ≥40 — produced a multivariable prediction model designed to address a practical clinical question: In a patient with presumed MGUS, can we predict whether their bone marrow actually harbors ≥10% plasma cells (i.e., SMM or worse) using only non-invasive laboratory data? (44,45)

Published in Annals of Internal Medicine (2024), this model uses only commonly available laboratory parameters — no cytogenetics, no bone marrow biopsy, no imaging required:

iStopMM Model Variables:

The model outputs a continuous predicted probability (0–100%) that a patient has ≥10% bone marrow plasma cells. This allows clinicians to make informed decisions about whether to proceed with bone marrow biopsy.

Performance (derivation cohort, n=1,043 screened MGUS patients):

• At a 10% predicted probability threshold: 93.3% sensitivity, 33.7% specificity, 85.0% NPV
• The high NPV means that if the model predicts a low probability, the negative predictive value is strong — bone marrow biopsy can likely be safely deferred

External Validation (Montefiore Medical Center, Bronx, 2025):

Critically, the iStopMM model was developed in a genetically homogeneous Icelandic (predominantly White) population. It was subsequently validated in a racially and ethnically diverse Bronx cohort (52.6% African American, 23.2% Hispanic/Latino) and achieved an AUROC of 0.78 (CI 0.71–0.85), demonstrating reasonable discriminatory performance across populations (46).

Clinical Pearl: The iStopMM model is uniquely valuable for the nephrology and primary care setting because it uses only laboratory values already available from the MASS-FIX/SPEP workup. For the case in Section 7, the IgA lambda isotype, M-protein of 0.118 g/dL, and the immunoparesis pattern (IgG 305, IgM 22) can all be entered into the iStopMM model to generate a predicted probability of ≥10% marrow plasma cells — helping guide the decision of whether bone marrow biopsy is warranted without requiring referral to hematology/oncology first.

Key iStopMM Findings Beyond the Prediction Model:

The iStopMM program has generated several additional clinically important findings:

• MGUS prevalence: ~5% of the Icelandic population age ≥40 has MGUS, higher than prior estimates (44)
• SMM prevalence: 0.53% of individuals age ≥40, with >1/3 having intermediate- or high-risk disease by 20/2/20 criteria (45)
• FLC reference ranges in CKD: The iStopMM CKD substudy established the eGFR-adjusted FLC ratio intervals used in Section 7.3 (30)
• Revised FLC reference ranges for normal renal function: Proposed narrower reference intervals that reduced false-positive LC-MGUS diagnoses by >80% (47)
• Infection risk in SMM: Patients with SMM have significantly more infections than MGUS patients or healthy controls, partially explained by immunoparesis — supporting monitoring and preventive strategies even before progression to MM (45)
• Venous thrombosis: MGUS is associated with increased risk of venous (HR 1.43) but not arterial thrombosis, introducing the concept of “monoclonal gammopathy of thrombotic significance” (48)
• Hypercalcemia: Transient hypercalcemia in MGUS/SMM patients is common (7.5%) and associated with higher progression risk (45)

4.4 Mayo 2018 “20/2/20” Model for Smoldering Myeloma

Lakshman et al. (2018) proposed a simplified model for SMM risk stratification, incorporating the revised 2014 IMWG diagnostic criteria (5):

Progression Risk by Risk Group:

This model has been validated by the IMWG (24) and has been recommended as a standard for clinical trial stratification (25). A 2024 Mayo Clinic study of 406 SMM patients confirmed its utility: among untreated high-risk patients (n=71), 72% progressed by last follow-up, with the most common myeloma-defining events being bone lesions (37%), anemia (35%), hypercalcemia (8%), and renal failure (6%) (26).

Clinical Pearl: The Mayo 2018 model applies not only at diagnosis but also during follow-up. Patients initially classified as low-risk who later develop evolving biomarkers (rising M-protein, increasing sFLC ratio, or expanding bone marrow plasmacytosis) should be reclassified and considered for early intervention (25,26).

4.4 Evolving M-Protein Patterns

An emerging refinement to the 20/2/20 model incorporates evolving patterns: a >10% and >0.2 g/dL increase in M-protein, or a >25% and >50 mg/L increase in involved sFLC within one year of SMM diagnosis, independently predicts accelerated progression (HR 5.02 and 3.66, respectively) (27). When added to the 20/2/20 model, these evolving patterns improved discrimination between risk groups.

5.1 Revised International Staging System (R-ISS)

Once MM is confirmed, the R-ISS (Palumbo et al., 2015) provides prognostic staging using widely available biomarkers (28):

R-ISS Components:

R-ISS Staging and Outcomes (median follow-up 46 months):

Validated in 3,060 patients across 11 international trials (28).

5.2 Second Revision (R2-ISS)

D’Agostino et al. (2022) proposed R2-ISS through the European Myeloma Network HARMONY project (n=10,843), adding 1q gain/amplification (1q+) as an additional weighted risk factor (29). This additive scoring system assigns points: ISS III (1.5 pts), ISS II (1.0 pt), del(17p) (1.0 pt), elevated LDH (1.0 pt), t(4;14) (1.0 pt), 1q+ (0.5 pts), yielding four risk categories with improved stratification of intermediate-risk patients.

5.3 mSMART: Mayo Stratification of Myeloma and Risk-Adapted Therapy

mSMART is the primary cytogenetic risk classification system used by oncologists to guide treatment selection (34,35). Unlike the R-ISS (which is a prognostic staging system), mSMART directly informs treatment intensity — patients with high-risk cytogenetics receive more aggressive regimens.

mSMART Cytogenetic Risk Classification (Updated 2024):

Clinical Pearl: The “double-hit” and “triple-hit” myeloma concepts (Rajkumar, 2024 update) represent a critical recent advance. Patients with two or more concurrent high-risk cytogenetic abnormalities have markedly worse outcomes than those with a single high-risk factor and are increasingly treated with intensified regimens including quadruplet induction (anti-CD38 + VRd) followed by tandem transplant in eligible patients (34).

Minimum FISH Panel (IMWG/mSMART):

The IMWG recommends that FISH testing be performed on CD138-sorted plasma cells (not unsorted marrow) and must include at minimum (35,36):

5.4 IMWG Consensus on High-Risk Multiple Myeloma (2025)

The IMS/IMWG published updated consensus recommendations on the definition of high-risk MM in 2025, formally incorporating the double-hit concept and emphasizing that risk should be assessed not just at diagnosis but also at relapse, where acquisition of new high-risk abnormalities (clonal evolution) can reclassify a previously standard-risk patient as high-risk (36).

5.5 Durie-Salmon Staging System (Historical)

The original staging system (1975), still occasionally referenced, estimates tumor burden based on clinical parameters (37):

The Durie-Salmon system has been largely supplanted by the ISS/R-ISS for prognostication but remains in some oncology literature and EMR templates.

5.6 IMWG Uniform Response Criteria

Oncologists use the IMWG response criteria to assess treatment efficacy. These are directly relevant for monitoring because they rely on the same M-protein and FLC measurements used for diagnosis (38):

Clinical Pearl: The introduction of MASS-FIX has created a practical dilemma: patients may achieve “CR” by conventional immunofixation but still have detectable M-protein by mass spectrometry. This concept — mass spectrometry-defined minimal residual disease (MRD) — is being increasingly incorporated into clinical trials and may eventually redefine response criteria (6,7).

5.6a IMWG Minimal Residual Disease (MRD) Criteria

As therapies have improved, deeper responses have become achievable, requiring more sensitive assessment methods. The IMWG (2016) formally defined MRD categories beyond stringent CR (40):

IMWG MRD Response Categories:

Methods for MRD Assessment:

Clinical Pearl: Mass spectrometry (MASS-FIX and QIP-MS) is emerging as a complementary MRD tool because it is serum-based — allowing serial monitoring without repeated bone marrow biopsies. Puig et al. (Blood 2024) showed that mass spectrometry and next-generation flow cytometry achieve similar prognostic value for single time-point MRD assessment in transplant-eligible myeloma patients (41). This positions MASS-FIX not just as a diagnostic tool but as a potential MRD monitoring platform.

5.6b The Original ISS (Pre-Revision)

For historical context and because many published studies and oncology EMR templates still reference the original ISS (Greipp et al., 2005), it is important to include this system (42). The ISS uses only two readily available laboratory values:

Nephrology caveat: β2-microglobulin is a low-molecular-weight protein freely filtered by the glomerulus and reabsorbed by proximal tubules. In CKD, β2-microglobulin rises due to reduced renal clearance — not necessarily increased tumor burden. This means ISS stage III may overclassify patients with concurrent CKD. However, a landmark study (Dimopoulos et al., Annals of Oncology 2012) demonstrated that the ISS retained independent prognostic significance even when stratified by CKD stage, suggesting that while β2-microglobulin is confounded by renal function, the ISS remains prognostically useful in patients with renal impairment (43).

5.7 IMWG 2020 SMM Risk Stratification Model

Building on the Mayo 2018 “20/2/20” model, the IMWG 2020 validation added cytogenetic abnormalities — t(4;14), t(14;16), and +1q — as additional risk factors (24):

5.8 AL Amyloidosis Staging Systems

For patients where the differential includes AL amyloidosis (as with the lambda-involved case in Section 7), oncologists use cardiac biomarker-based staging to determine prognosis and guide treatment intensity (39):

Mayo 2004 AL Amyloidosis Staging:

Revised Mayo 2012 Staging (adding dFLC):

The 2012 revision added the difference between involved and uninvolved free light chains (dFLC) as an independent prognostic factor, with a threshold of ≥18 mg/dL (180 mg/L), creating a 4-stage system with stage IV carrying the worst prognosis (39).

Clinical Pearl: The dFLC threshold of 18 mg/dL (180 mg/L) in AL amyloidosis staging requires accurate FLC measurement — making the unit conversion issue (mg/dL vs. mg/L) clinically critical. Misreading 18 mg/dL as 18 mg/L (which is within the normal absolute FLC range) would completely misclassify the patient.

5.9 IMWG Minimal Residual Disease (MRD) Assessment

MRD has become the strongest prognostic biomarker in treated MM and is increasingly used as a surrogate endpoint in clinical trials. The 2025 IMWG guideline updates formally incorporate mass spectrometry and MRD into the response framework (40,41).

MRD Assessment Methods:

IMWG MRD Response Categories (2016/2025 update):

Clinical Pearl: Mass spectrometry is creating a paradigm shift in MRD monitoring. Patients achieving “CR” by conventional immunofixation may still have detectable M-protein by MASS-FIX or clonotypic peptide MS assays. The 2025 IMWG updates prioritize serum FLC monitoring over 24-hour urine collection and formally incorporate mass spectrometry into the monitoring framework. The “deep MRD-negative” category — introduced as an aspirational concept potentially pointing toward cure — requires mass spectrometry negativity as one criterion (40,41).

5.10 IPSSWM: Waldenström Macroglobulinemia Prognostic Scoring

Because the MASS-FIX panel includes IgM kappa (MK) and IgM lambda (ML) channels, detection of an IgM monoclonal protein raises the differential of Waldenström macroglobulinemia (WM / lymphoplasmacytic lymphoma). Oncology uses two scoring systems for symptomatic WM (42,43):

Original IPSSWM (Morel et al., 2009):

Five adverse factors: age >65, hemoglobin ≤11.5 g/dL, platelets ≤100 × 10⁹/L, β2-microglobulin >3 mg/L, serum IgM >7.0 g/dL.

MSS-WM (Modified Staging System, Zanwar et al., 2024):

A simplified 3-variable model now preferred: age (≤65 = 0 pts, 66–75 = 1 pt, >75 = 2 pts), albumin <3.5 g/dL (1 pt), LDH > ULN (2 pts).

Molecular markers: MYD88 L265P mutation is present in >90% of WM and is now routinely assessed at diagnosis. Its absence (MYD88 wild-type) is associated with inferior outcomes and may suggest alternative diagnoses (e.g., marginal zone lymphoma with IgM paraprotein) (43).

6.1 Renal Presentations of Myeloma

Renal impairment (creatinine clearance <40 mL/min or creatinine >2 mg/dL) is one of the CRAB criteria defining myeloma. Among high-risk SMM patients who progressed to MM in the Mayo 2024 study, renal failure was the myeloma-defining event in 6% of cases (26). Light chain cast nephropathy (myeloma kidney) remains the most common cause of myeloma-associated AKI.

6.2 The “SPEP-Negative” Renal Presentation

Light chain-only myeloma can present with severe AKI and a normal or unremarkable SPEP. The M-protein is not detectable because intact immunoglobulin is not overproduced—only free light chains are secreted. In this scenario:

• SPEP may show hypogammaglobulinemia but no M-spike
• sFLC ratio will be markedly abnormal
• MASS-FIX (where available) has superior sensitivity for detecting light chain-only disease (6,19)
• Urine testing (urine MASS-FIX or urine immunofixation) should be obtained

6.3 Free Light Chain Ratio in Renal Failure

The κ/λ FLC ratio reference range (0.26–1.65) was established in patients with normal renal function. In CKD, differential renal clearance of κ vs. λ light chains can alter the ratio independent of clonality. The extended reference range for renal impairment (approximately 0.37–3.1) should be applied in CKD patients to avoid misclassification (20). This was specifically noted as a limitation in the 2025 Mayo Clinic MGUS validation study (20).

6.4 Monoclonal Gammopathy of Renal Significance (MGRS)

Not all renal injury from monoclonal proteins meets criteria for myeloma. MGRS describes renal disease caused by a monoclonal immunoglobulin produced by a B-cell or plasma cell clone that does not meet criteria for overt malignancy. MGRS is important because it requires treatment directed at the clone despite “MGUS-level” M-protein and marrow involvement.

Clinical Pearl: A nephrologist who identifies a monoclonal protein in the setting of unexplained renal disease should not assume the paraprotein is an innocent MGUS simply because the M-protein is <3 g/dL and marrow plasma cells are <10%. Renal biopsy is essential to determine whether the monoclonal protein is directly causing renal injury.

7.1 Understanding the MASS-FIX Panel Structure

The MASS-FIX panel (QMPTS — Quantitative Monoclonal Protein by Time-of-flight Spectrometry) systematically tests for monoclonal proteins across all six major heavy chain/light chain pairings. The two-letter codes reflect this structure:

When a monoclonal protein is detected in any channel, it means the mass spectrometer has identified an immunoglobulin of that specific heavy/light chain pairing with a unique molecular mass signature that distinguishes it from polyclonal background. “NA” means no monoclonal protein was detected in that channel.

Additional MASS-FIX Fields:

7.2 Understanding Units: The g/dL vs. g/L Discrepancy

A critical source of confusion exists between M-protein units reported by different laboratories and the units used in scoring system thresholds.

Conversion: 1 g/dL = 10 g/L

The MASS-FIX panel reports M-protein in g/dL. The IMWG 2014 criteria and most US-based thresholds use g/dL. European literature and the original Mayo 2018 “20/2/20” publication (Lakshman et al.) use g/L — hence the name “20/2/20” referring to 20 g/L (= 2 g/dL), not 20 g/dL. Failure to recognize this unit difference can lead to a tenfold misinterpretation of thresholds.

⚠️ Warning: Always confirm which unit system a laboratory is using before interpreting M-protein levels against diagnostic thresholds. A reported M-protein of “2” could mean 2 g/dL (= 20 g/L, above the SMM risk threshold) or 2 g/L (= 0.2 g/dL, below SPEP detection limits), depending on the laboratory. This is a common source of clinical error.

7.3 Serum Free Light Chains: Reference Ranges, Renal Adjustment, and Units

Serum free light chains (sFLC) are measured separately from the M-protein quantification on MASS-FIX. The standard assay is the Freelite™ (The Binding Site) platform.

Standard Reference Ranges (Normal Renal Function):

The unit discrepancy for FLC: Most reference laboratories report sFLC in mg/L, but some US labs report in mg/dL. Since 1 mg/dL = 10 mg/L, a reported kappa of “1.5” could be 1.5 mg/dL (= 15 mg/L, normal) or 1.5 mg/L (low end of normal). The IMWG myeloma-defining threshold of involved FLC ≥100 mg/L (= 10 mg/dL) must be interpreted in the correct units. Always verify the reporting units.

Why the Normal Ratio Is Not 1:1

In healthy individuals, plasma cells produce kappa and lambda light chains in approximately a 2:1 ratio (matching intact immunoglobulin production). However, because free kappa is a smaller monomer (22.5 kDa) that is filtered and cleared by the kidneys much more rapidly than free lambda (a 45 kDa dimer), the steady-state serum level of free lambda is relatively higher than free kappa (3,14). This is why the normal κ/λ ratio is 0.26–1.65 rather than 2:1 — renal clearance normalizes the serum ratio downward.

Renal Adjustment of FLC Reference Ranges

Because the kidneys are the primary clearance route for free light chains, declining renal function causes accumulation of both kappa and lambda FLC in serum. Kappa (monomer) is more affected by reduced GFR than lambda (dimer), causing the κ/λ ratio to rise. Using standard reference ranges in CKD patients leads to high false-positive rates.

The iStopMM study (2022) established eGFR-based reference intervals for FLC ratio in 6,461 participants with eGFR <60 mL/min/1.73m² (30):

Clinical Pearl: In a patient with CKD stage 3b and a κ/λ ratio of 2.5, the standard reference range would flag this as abnormal (>1.65) and potentially trigger an unnecessary workup for plasma cell dyscrasia. The iStopMM eGFR-adjusted range (0.48–3.38) correctly identifies this as within normal limits for that level of renal function. For nephrologists, applying the renal-adjusted FLC ratio is essential to avoid false-positive diagnoses of LC-MGUS in CKD patients (30).

Absolute FLC Levels in CKD (iStopMM Data):

7.4 Kappa vs. Lambda Predominance: Multiple Myeloma vs. AL Amyloidosis

The light chain type involved in a monoclonal gammopathy carries important diagnostic implications. The pattern of kappa vs. lambda predominance differs significantly between multiple myeloma and AL amyloidosis.

Normal Physiology: Healthy individuals produce kappa and lambda light chains in approximately a 2:1 ratio (kappa predominant), both as part of intact immunoglobulins and as free light chains (31).

Multiple Myeloma:

• Kappa predominance is maintained, reflecting the normal 2:1 production ratio
• Approximately 60–65% of MM cases involve kappa light chains; 35–40% involve lambda (31)
• A high κ/λ ratio (>>1.65) suggests kappa-involved clonal disease
• A very low κ/λ ratio (<<0.26) suggests lambda-involved clonal disease
• The myeloma-defining SLiM criterion is an involved/uninvolved FLC ratio ≥100 (in either direction) (1)

AL Amyloidosis:

• Lambda predominance — the κ:λ ratio is inverted to approximately 1:3 (lambda predominant) (31,32)
• Approximately 70–75% of AL amyloidosis cases involve lambda light chains; 25–30% involve kappa
• Lambda light chains — particularly those encoded by the Vλ6 germline gene — are inherently more amyloidogenic (have greater propensity to misfold and deposit as amyloid fibrils) (32,33)
• Lambda light chain AL is associated with cardiac and renal involvement
• Kappa light chain AL is less common but is associated with hepatic involvement (31)
• Light chain N-glycosylation (detected by MASS-FIX) is an additional risk marker for AL amyloidosis (19)

Diagnostic Pattern Recognition:

Clinical Pearl: When evaluating a patient with a lambda-predominant monoclonal protein (low κ/λ ratio), particularly with a small clone and unexplained proteinuria, cardiomyopathy, neuropathy, or nephrotic syndrome, AL amyloidosis should be actively excluded. The combination of lambda light chain involvement + small M-protein + organ dysfunction should trigger a tissue biopsy with Congo red staining. MASS-FIX glycosylation results provide additional risk information (19).

Interpreting the FLC Ratio Direction:

7.5 Interpreting MASS-FIX Results: What Normal and Abnormal Mean

A. M-Protein Channels (GK, GL, AK, AL, MK, ML)

For each of the six isotype channels, the result is either “NA” (no monoclonal protein detected) or a quantified value in g/dL with an “(H)” flag indicating abnormal.

Interpreting the M-protein value:

Clinical Pearl: When the M-protein is detectable on MASS-FIX but below SPEP detection limits, this does NOT automatically confer worse prognosis than a “negative” SPEP at another institution. It means the test is more sensitive. The clinical significance depends entirely on the full constellation: bone marrow plasma cell percentage, sFLC ratio, imaging, immunoparesis, and presence of end-organ damage.

B. Isotype-Specific Implications

The specific heavy chain/light chain combination detected carries diagnostic weight:

C. Glycosylation Field

D. Quantitative Immunoglobulins: Interpreting Immunoparesis

The quantitative immunoglobulin panel (IgG, IgA, IgM by nephelometry) is reported alongside MASS-FIX. The key finding to assess is immunoparesis — suppression of the uninvolved immunoglobulin classes.

Reference Ranges:

Interpreting Suppressed Immunoglobulins:

⚠️ Warning: Marked IgG suppression is clinically significant for infection risk regardless of the MGUS vs. MM classification. Serial monitoring of quantitative immunoglobulins is warranted, vaccination status should be optimized, and patients should be counseled about infection signs. The iStopMM program demonstrated that even SMM patients have significantly more infections than healthy controls, partially attributable to immunoparesis (45).

E. Therapeutic Antibody Field

7.6 Applying Risk Models to MASS-FIX Data

With a completed MASS-FIX panel and quantitative immunoglobulins, the following risk models can be partially or fully assessed:

Clinical Pearl: The MASS-FIX panel plus quantitative immunoglobulins provides enough data to run the iStopMM prediction model and partially assess the Mayo 2005 MGUS and PETHEMA models. The next essential step for any abnormal panel is ordering a serum free light chain assay with κ/λ ratio — this single additional test unlocks the Mayo 2005 model (third factor), the Mayo 2018 “20/2/20” model (second factor), and the SLiM criteria (first criterion). For a nephrologist, the renal-adjusted FLC ratio (Section 7.3) must be applied if eGFR <60. If clinical concern for AL amyloidosis exists (lambda involvement, organ dysfunction), add NT-proBNP, troponin, and 24-hour urine protein.

8.1 The Two Questions and the Tests That Answer Them

The core reframe: In AL amyloidosis, the light chains are the disease — the amyloidogenic free light chain is the direct pathogenic agent. In MGUS/MM, the light chain ratio is a marker of clonality. This distinction explains why FLC is central to amyloid evaluation and supplementary to myeloma evaluation.

8.2 Why Absolute FLC Levels Are Unreliable in CKD — But the Ratio Remains Clinically Useful

This is the single most important practical point for nephrologists interpreting FLC results:

What happens to FLC in CKD: - Both kappa and lambda free light chains are filtered and reabsorbed by the kidney - As GFR falls, both accumulate in serum — kappa (monomer, ~22.5 kDa) more so than lambda (dimer, ~45 kDa), because the smaller monomer is more dependent on glomerular filtration - By CKD stage 3b (eGFR 30–44), median kappa is ~30 mg/L and median lambda is ~25 mg/L — roughly double the upper normal limits - By CKD stage 4–5, medians are ~48 mg/L (kappa) and ~35 mg/L (lambda) — further elevated - The absolute values are therefore almost always flagged as “H” (high) in CKD patients, regardless of clonal disease

What this means clinically:

The practical rule: In CKD, look at the ratio, not the absolutes. Apply the iStopMM eGFR-adjusted reference intervals (Section 7.3). Absolute FLC values become interpretable again only when the ratio is abnormal — at that point, the absolute level of the involved chain quantifies disease burden.

8.3 The dFLC in CKD: Use With Caution

For AL amyloidosis staging, the dFLC (difference between involved and uninvolved FLC) is the key metric: dFLC ≥ 180 mg/L is a Mayo 2012 staging criterion. But in CKD, both kappa and lambda are elevated — so the dFLC may be artificially inflated by the background renal retention of the uninvolved chain.

Example from Mr. Felton’s case: - Lambda: 285 mg/L (involved) - Kappa: 53.1 mg/L (uninvolved) - dFLC: 231.9 mg/L

In a patient with advanced CKD (Stage 4), median lambda is ~35 mg/L and median kappa is ~48 mg/L from CKD alone. Some of Mr. Felton’s lambda elevation reflects CKD-related retention, but the ratio of 0.1863 — far below the renal-adjusted lower limit of ~0.54 for CKD stage 4 — confirms massive clonal lambda excess that cannot be explained by renal failure alone. The dFLC of 232 mg/L likely overestimates true clonal production somewhat, but the direction and magnitude are unambiguously abnormal.

Practical approach to dFLC in CKD: 1. Confirm clonality first using the ratio (renal-adjusted) 2. Once clonality is confirmed, the dFLC provides staging information 3. Recognize that in CKD, the dFLC may be modestly inflated — use the ratio as the primary diagnostic anchor, dFLC as a supplementary staging tool 4. Serial dFLC is still the standard for monitoring treatment response (hematologic response criteria require ≥50% reduction in dFLC)

8.4 Practical Decision Framework by Clinical Scenario

8.5 The Nephrologist’s Revised Mental Model

Before the Felton case, the mental model many nephrologists carry is:

“FLC levels are always high in CKD — I don’t spend much time on them. AL amyloidosis = nephrotic syndrome.”

The revised model, validated by Mr. Felton’s case and the molecular biology of cardiotrophic lambda AL:

“Absolute FLC levels in CKD are physiologically elevated and largely uninterpretable in isolation. The ratio — corrected for GFR — is what I should be looking at. A ratio that falls outside the renal-adjusted reference interval signals clonal disease regardless of the absolute levels. In any patient with unexplained organ dysfunction (cardiac, renal, neurologic, hepatic) and a lambda-predominant FLC ratio below the renal-adjusted lower limit, AL amyloidosis is in the differential until proven otherwise — regardless of whether nephrotic syndrome is present.”

Clinical Pearl — The Two-Test Rule for Amyloid Screening in CKD: 1. Is the κ/λ ratio abnormal for the patient’s GFR? (Use iStopMM eGFR-adjusted intervals, Section 7.3) 2. If yes: what is the involved chain, and does the pattern fit the organ dysfunction? Lambda excess (low ratio) + cardiac dysfunction → AL lambda amyloidosis until proven otherwise Kappa excess (high ratio) → AL kappa or kappa myeloma Ratio normal for GFR → FLC elevation is physiologic; pursue monoclonal screen for MGUS/MGRS/MM